Search
Clobetasol propionate
go.drugbank.com/drugs/DB01013ApprovedInvestigational[L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974. … [A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809]
Products: PMS-clobetasol, PMS-clobetasol CreamConjugated estrogens
go.drugbank.com/drugs/DB00286ApprovedInvestigationalIt also presents a large number of unidentified molecules with weak estrogenic activity as well as non-human molecules when it is obtained from pregnant mares urine. … [T484] The currently approved product of conjugated estrogens was developed by Wyeth Ayerst and FDA approved in 2003.[L5608]
Products: PMS-conjugated Estrogens C.S.D.Ticlopidine
go.drugbank.com/drugs/DB00208ApprovedTiclopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke.
Products: PMS-ticlopidineMethocarbamol
go.drugbank.com/drugs/DB00423ApprovedInvestigationalVet approvedMethocarbamol was developed in the early 1950s as a treatment for muscle spasticity and the associated pain.[A178441,A178450] It is a guaiacol glyceryl ether. … [L6295] Methocarbamol was FDA approved on 16 July 1957.[L6265]
Mixtures: REMISOL PLSProducts: PMS-methocarbamol Inj 100mg/mlLeflunomide
go.drugbank.com/drugs/DB01097ApprovedInvestigationalLeflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Products: PMS-leflunomide, AS-LUNEX 10 MG TABLET, 30 ADETFluoxetine
go.drugbank.com/drugs/DB00472ApprovedInvestigationalVet approvedFluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). … [A181673] It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies
Products: PMS-fluoxetine, PMS-fluox Capsules 20mgChloramphenicol
go.drugbank.com/drugs/DB00446ApprovedInvestigationalVet approvedWithdrawnIt has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. … (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this
Mixtures: Actinac PwsProducts: PMS-chloramphenicol Ophthalmic Ointment, PMS-chloramphenicol Ophthalmic Soln 0.5%Fluvoxamine
go.drugbank.com/drugs/DB00176ApprovedInvestigationalFluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. … It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Products: PMS-fluvoxamineThiotepa
go.drugbank.com/drugs/DB04572ApprovedInvestigationalIt is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.
Products: Thiotepa - (pws 15 Mg/vial)Silodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigational[A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada. … Silodosin is available as oral capsules with common trade names Rapaflo and Urorec. It is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults.
Products: PMS-silodosin